Improvement of peripheral endothelial dysfunction by protein tyrosine phosphatase inhibitors in heart failure

Circulation. 2006 Dec 5;114(23):2498-507. doi: 10.1161/CIRCULATIONAHA.106.630129. Epub 2006 Nov 13.


Background: Chronic heart failure (CHF) induces endothelial dysfunction characterized by a decrease in nitric oxide (NO) production in response to flow (flow-mediated dilatation [FMD]). Because activation of endothelial NO synthase (eNOS) by flow requires tyrosine phosphorylation, we tested whether endothelial dysfunction could be corrected by increasing phosphotyrosine levels using protein tyrosine phosphatase (PTP) inhibitors and especially inhibitors of PTP1B.

Methods and results: CHF was induced by coronary ligation in mice, and FMD was assessed in isolated and cannulated mesenteric artery segments (2 mm in length and <300 microm in diameter). CHF almost abolished FMD but only moderately affected the response to acetylcholine. In mice with CHF, the PTP1B inhibitors AS279, AS098, and AS713 restored FMD to levels similar to those of normal mice. This restoration was reduced by inhibitors of eNOS and phosphatidylinositol-3 kinase. Polymerase chain reaction and Western blot showed that arteries express PTP1B, and this expression was not affected by CHF. Immunolocalization revealed the presence of PTP1B in the endothelium and the adventitia. Flow induced a transient eNOS phosphorylation that was absent in CHF. PTP1B inhibition stimulated early eNOS phosphorylation and increased phosphorylation of Akt.

Conclusions: Our results demonstrate for the first time that PTP1B inhibitors may be potent treatments for endothelial dysfunction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcholine / pharmacology
  • Animals
  • Cardiac Output, Low / enzymology*
  • Cardiac Output, Low / pathology
  • Cells, Cultured
  • Coronary Vessels / drug effects*
  • Coronary Vessels / pathology
  • Coronary Vessels / physiopathology
  • Endothelium, Vascular / drug effects*
  • Endothelium, Vascular / pathology
  • Endothelium, Vascular / physiopathology
  • Enzyme Inhibitors / pharmacology*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Nitric Oxide / physiology
  • Nitric Oxide Synthase Type III / antagonists & inhibitors
  • Phosphatidylinositol 3-Kinases / physiology
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphorylation / drug effects
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • Protein Tyrosine Phosphatases / antagonists & inhibitors*
  • Rats
  • Rats, Wistar
  • Vasodilation / drug effects
  • Vasodilation / physiology
  • Vasodilator Agents / pharmacology


  • Enzyme Inhibitors
  • Phosphoinositide-3 Kinase Inhibitors
  • Vasodilator Agents
  • Nitric Oxide
  • Nitric Oxide Synthase Type III
  • Protein Tyrosine Phosphatase, Non-Receptor Type 1
  • Protein Tyrosine Phosphatases
  • Ptpn1 protein, mouse
  • Ptpn1 protein, rat
  • Acetylcholine